七年春节坚守，智能制造助力医药保供加速 除夕夜，在辽宁方大集团东北制药细河原料药厂区202分厂外包装操作室内，伴随着机器轰鸣声，一箱 箱盐酸小檗碱有序完成包装。 "设备专人负责、实时巡检、记录留痕，每一道工序都不能马虎。"林艳一边紧盯设备参数，一边向贝壳 财经记者介绍，"我们优化了包装节奏，减少工序等待，1月份已经超额完成产量计划，就是要全力以赴 冲刺一季度'开门红'，保障市场供应不脱节。" 进入东北制药28年，今年已是林艳第七次在岗位上度过春节。 春节前的排班，从来不是一件简单的事。但在林艳眼里，这份"难题"却总能在默契中化解。 "外地的员工，家远的，优先让他们先回，别耽误了团圆。"这是每年排班时不成文的规矩。车间里，离 家近的、本地的同事会主动往前站，等外地同事返岗后，大家再轮换着休息。 春节期间，东北制药202分厂盐酸小檗碱后部工段的灯火依旧通明。工段长林艳又一次出现在春节值班 表里，这已经是她连续第七年在岗位上度过春节假期。 作为医药生产线上的一名"老兵"，林艳深知自己手中生产的原料药产品，都可能是下游药企和患者节日 里的急需。而在医药企业的生产厂区和药房门店内，像林艳这样坚守岗位的员工随处可见：十多 ...

Core Viewpoint - Northeast Pharmaceutical is committed to strategic transformation through innovation and management reform, aiming to enhance operational quality and transition from a traditional chemical drug leader to a biopharmaceutical leader [1] Group 1: Strategic Focus and Innovation - The company is focusing on strategic acquisitions, particularly the acquisition of Dingcheng Peptide Source, to commercialize innovative results in cell therapy [1][2] - Northeast Pharmaceutical has established a product matrix covering various fields, including oncology and autoimmune diseases, driven by a dual strategy of "innovative drugs + generic drugs" [2][3] - The company has developed over 10 tumor-targeted cell immunotherapy products, with DCTY1102 injection expected to be the first domestic TCR-T cell drug entering Phase I clinical trials targeting KRAS G12D [2] Group 2: Management and Efficiency - Since implementing mixed ownership reform in 2018, the company has adopted new management and incentive models, enhancing operational quality and efficiency [4] - The company has achieved a 20.5% year-on-year reduction in sales expenses and an 88% increase in R&D expenses, reflecting precise resource allocation [4] - Financial stability is indicated by a decreasing debt-to-asset ratio and a significant reduction in current liabilities, lowering short-term repayment risks [4] Group 3: Global Expansion - Northeast Pharmaceutical has a strong international presence, exporting products to over 100 countries, with a notable increase in overseas sales revenue of 9.02 billion yuan, up 26.3% year-on-year [6][7] - The company is optimizing its marketing system to enhance market share and brand influence, particularly in the competitive vitamin C and phosphomycin markets [6][7] - The global layout provides a broader platform and resources, allowing the company to diversify market risks and enhance its competitive edge in international markets [7]

Core Insights - Liaoning Fangda Group Northeast Pharmaceutical's Q1 2025 report shows a significant increase in R&D investment by 88% year-on-year, indicating a strategic shift towards R&D-driven growth and quality enhancement over mere revenue increase [2][4] Group 1: Quality Improvement and Financial Health - Despite a slight revenue increase of 0.36% in Q1 2025, the company achieved steady improvement in operational quality through refined management and structural optimization [2] - Sales expenses decreased by 20.5% year-on-year, while management expenses also reduced, and R&D expenses rose strategically to 32 million yuan, reflecting precise resource allocation [2] - The company's debt-to-asset ratio fell to 58.82%, a decrease of 2.63 percentage points from the beginning of the year, indicating enhanced financial health and reduced short-term repayment risks [2] Group 2: Innovation and Product Development - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," creating a product matrix covering various therapeutic areas including neurology, digestion, endocrinology, oncology, and autoimmune diseases [3] - The company is accelerating its strategic layout in cutting-edge fields, particularly in tumor immunotherapy, with over 10 immune therapy products targeting diseases like pancreatic cancer and colorectal cancer [4] - A notable product in development is a TCR-T cell drug targeting KRASG12D, which is expected to be the first of its kind in China to enter Phase I clinical trials [4] Group 3: Global Market Expansion - The company is leveraging its international presence to enhance its global sales network, with its main products exported to over 100 countries and regions [5] - The global sales strategy has effectively diversified market risks and established sustainable revenue capabilities [5] - Although there may be short-term profit fluctuations due to increased R&D investments, the strategic transformation is showing initial positive results, positioning the company for future growth cycles as innovative therapies are commercialized [5]

Core Viewpoint - Northeast Pharmaceutical has demonstrated a notable performance in quality transformation through structural adjustments in the first quarter of 2025, despite a slight revenue increase of only 0.36% [1] Group 1: Financial Performance - The company achieved a 20.5% year-on-year reduction in sales expenses and a simultaneous decrease in management expenses, while strategically increasing R&D expenses to 32 million yuan, an 88% year-on-year surge [2] - As of the end of the first quarter, the company's debt-to-asset ratio decreased to 58.82%, down 2.63 percentage points from the beginning of the year, indicating improved financial health and reduced short-term repayment risks [2] Group 2: Innovation and R&D - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," covering multiple therapeutic areas including the nervous system, digestive system, and oncology, which highlights its long-term growth potential [3] - The company has accelerated its strategic layout in cutting-edge fields of innovative drugs, with a significant increase in R&D funding aimed at tumor immunotherapy, a key trend in the global pharmaceutical industry [3] - The company has developed over 10 targeted cell immunotherapy products for various cancers, with DCTY1102 injection expected to be the first TCR-T cell drug targeting KRAS G12D to enter Phase I clinical trials in China [3] Group 3: Competitive Strategy - The company has consolidated its competitive advantage through a "combination of innovation and imitation" strategy, with 243 product specifications included in the national medical insurance catalog and 120 in the national essential drug list, providing a stable foundation for performance growth [4] - This dual-driven model of "innovative drugs leading and generic drugs supporting" ensures short-term performance certainty while opening up long-term growth opportunities [4] Group 4: Global Strategy - The company is leveraging its international gene advantage to enhance its global sales network, with its leading products exported to over 100 countries and regions, thereby diversifying market risks and creating sustainable revenue streams [5] - Despite short-term profit fluctuations, the company's strategic transformation is showing initial results, with management reforms and future-oriented R&D investments leading to significant improvements in operational quality [5] - As the innovative drug pipeline matures and the global strategy deepens, Northeast Pharmaceutical is transitioning from a traditional pharmaceutical company to a leader in biotechnology, with the commercialization of cell therapies expected to initiate a new growth cycle [5]